Well its all over most boards now that you and your pump crew are working BNHLF and you can bet
many of us have went to the SEC web page and filed a report and that my friend will place you
on their watch list... Trust me I know how to handle people like you and pumping this board was
not to your best interest...
Yes, that or partner out with Abbott, J they have a limited window here to make some type of deal and it's not out of the question, but their cash IS running out, they need to do something and do it fast IMO, this test is great technology without a doubt. The problem is IMO that it's run by a board that seem to be incompetent imho mind you, they are not the sharpest tools in the shed.
If you believe what you say was left out......you would then conclude the best course of action would be to sell the company to a reputable pharma, medical company that has the contacts and credibility of the medical field in the United States and abroad. Abbott...........???
They will need cash in the 2nd Q, They only have enough to cover April and half of may if their lucky. The Company will need to raise additional funds to finance its operations and service its existing debt through the second quarter of 2015 and beyond.
Why do you leave out = The above circumstances along with the Company’s history and near term forecast of incurring net losses and negative operating cash flows raise substantial doubt regarding its ability to continue as a going concern through the second quarter of 2015 and beyond.
Excellent post......Great time for getting in IMO, should be soon when we hear the plan for going forward, sale of company most likely.p
1)FDA clearance of Galectin3 sales for prognosis of CHF patients Market size in USA approx. 6 million patients to be tested 1-3 times per year or more.
2)Abbott to lead sales of Galectin3 as 1st automated version in USA. BioMerieux ,Alere, and Siemens to follow suit for FDA clearance of Automated tests.
3) Insiders and Management own 86% of shares outstanding in an incredible show of confidence in the success of the company.
4)Company owns Patent for HF treatment using Gal3 inhibitors.
5)CardioScore is another Blood test developed by BGMD with huge potential CE approved. They just need Abbot's help here.
6)company owns Data to huge FDA approved BioImage study. Study worth over $20 million
7)company plans to file for other indications for use of Galectin3 to increase market testing size. ( ie CKD 26 million patients)
8) company hired Stifel & investment banker for strategic alternatives ( buyout- merger) in Nov 2014 to increase shareholder value.
1) they need to present a plan to Nasdaq to regain compliance and stay listed on Nasdaq
2) they will need cash after 2nd Q
Both negatives should easily be resolved given their backing (Insiders) and the fact Gal3 is FDA cleared now. Finish line has been reached. Abbott will monetize.IMHO. Please all do your own DD before investing. I did mine.GLTA
Sentiment: Strong Buy
They will get bought out first at $14 a share,then they will split 2 for one for fun.
Sentiment: Strong Buy
I know there was some chat about it a while back. Anyone have an update on the?
I don't see how they will up list without one ;(
Sentiment: Strong Sell
i too remember him stating that he sold out. i had assumed he bought back in because the amount of posts he makes.....strange for someone not invested to monitor and constantly post.
Actually if you see Lil's earlier post, you will see he was pumping this stock non stop. Then he says I have sold everything and started bashing it. I don't read anything posted by him. Just a waste of time.
i too once thought lil was legit as a poster but i no longer do. the way i see him...he is a board poster that keeps things stirred up.
far too many posts for one person...and it is a constant bash and rehash. i ignore all his posts now........
The only one manipulating this stock is the market maker, and for good reason, he knows it's not going anywhere soon, he can do what he wants, and that is his job, making a market